Aurobindo Pharma cash flow

Latest FY26

Cash from operations: ₹5,526cr+40.8% on FY25
Capital spending: ₹3,105cr+23.2% on FY25
Free cash flow: ₹2,422cr+72.4% on FY25
Cash from financing: −₹1,269cr₹120 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	1,778	1,649	1,522	1,245
	—	0.0	0.0	32.6	0.0
	—	352	440	268	0.0
	—	−329	−353	−286	0.0
	—	−2.3	0.0	0.0	0.0
	—	0.0	16.9	−2.7	−19.1
	—	221	58.7	−51.2	−38.1
	—	9.4	2.5	6.4	417
	—	54.6	0.0	0.0	0.0
	—	0.0	−12.1	−10.1	−13.0
	—	−1,500	−735	−1,304	−927
	—	−1,171	−862	−264	−432
	—	156	−172	0.0	−219
	—	0.0	0.0	−174	0.0
	—	−420	171	−669	−355
	—	1,282	−311	583	708
	—	1,057	937	317	233
	—	561	−332	−263	−124
	—	200	59.0	98.6	21.8
Cash from operating activities
	5,422	5,110	5,098	4,397	2,624
	—	2,248	558	−196	497
	—	7,358	5,656	4,201	3,121
	—	0.0	0.0	0.0	−146
	—	0.0	0.0	0.0	−129
	—	1,832	1,731	1,767	717
	—	5,526	3,925	2,435	2,387
Cash from investing activities
	—	2,686	1,968	2,780	2,404
	—	419	552	781	317
	—	46.3	2.8	60.3	11.1
	—	788	23.0	3.8	2,014
	—	5.9	111	179	2,457
	—	0.0	0.0	21.9	0.0
	—	303	11.4	0.0	197
	—	2.3	0.0	0.0	0.0
	—	329	347	281	147
	—	354	217	−1,189	−1,661
	—	−3,458	−1,875	−4,256	−3,978
Cash from financing activities
	—	0.0	930	0.0	0.0
	—	0.0	22.5	0.0	0.0
	—	720	2,723	1,478	2,458
	—	1,304	1,119	17.2	0.0
	—	109	110	147	92.5
	—	344	420	251	111
	—	232	0.0	264	440
	—	0.0	−1.0	0.0	0.0
	—	−1,269	120	800	1,814
	—	799	2,169	−1,021	223
	—	829	9.1	14.2	−0.1
	—	1,628	2,178	−1,007	223
	—	—	5,564	3,385	4,392
Reference items
	7,085	6,846	6,583	5,843	3,719
	20.3%	20.3%	20.8%	20.2%	15.0%
	2,422	2,422	1,405	−1,127	−334
	—	1,812	2,611	76.1	—
	₹41.70	₹41.70	₹24.19	−₹19.40	−₹5.74
	39.45×	—	—	—	—
	—	1.58×	1.13×	0.77×	1.24×
	—	1,832	1,731	1,767	717
	—	344	420	251	111

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AUROPHARMA₹1,644.80

Aurobindo Pharma Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA DRREDDY CIPLA FORTIS LUPIN ALKEM LAURUSLABS MANKINDMcap ₹95,530 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	1,244.6	1,521.7	1,649.4	1,778.2	—
+ Impairment Loss / (Reversal)	0.0	32.6	0.0	0.0	—
+ Finance Costs	0.0	268.1	440.4	352.3	—
+ Interest Income	0.0	-285.8	-353.2	-329.1	—
+ Dividend Income	0.0	0.0	0.0	-2.3	—
+ Fair Value (Gains) / Losses	-19.1	-2.7	16.9	0.0	—
+ Unrealised FX (Gain) / Loss	-38.1	-51.2	58.7	221.0	—
+ Other Non-cash Items	417.5	6.4	2.5	9.4	—
+ Other — Cash Effects are Investing / Financing	0.0	0.0	0.0	54.6	—
+ Other Reconciling Items	-13.0	-10.1	-12.1	0.0	—
Changes in Working Capital
+ Inventories	-926.7	-1,303.7	-735.5	-1,499.8	—
+ Trade Receivables — Current	-432.1	-264.2	-862.1	-1,170.7	—
+ Other Financial Assets — Current	-219.4	0.0	-171.6	155.6	—
+ Other Financial Assets — Non-current	0.0	-173.6	0.0	0.0	—
+ Other Current Assets	-355.0	-669.0	171.3	-420.3	—
+ Trade Payables — Current	707.7	582.8	-310.9	1,281.6	—
+ Other Financial Liabilities — Current	232.8	317.4	936.8	1,057.2	—
+ Other Current Liabilities	-124.1	-263.4	-331.5	560.7	—
+ Provisions — Current	21.8	98.6	59.0	199.6	—
Cash from Operating Activities
Profit Before Tax (per I/S)	2,624.2	4,397.2	5,098.0	5,110.3	5,422.1
+ Total Adjustments (incl. Working Capital)	496.8	-196.0	558.0	2,248.1	—
Cash from Operations (pre-tax)	3,120.9	4,201.2	5,656.0	7,358.4	—
+ Interest Received — Operating	-145.9	0.0	0.0	0.0	—
+ Interest Paid — Operating	-129.0	0.0	0.0	0.0	—
+ Income Taxes Paid	717.2	1,766.6	1,731.4	1,832.0	—
Cash from Operating Activities	2,386.8	2,434.5	3,924.6	5,526.4	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	2,403.8	2,780.3	1,967.9	2,685.8	—
+ Acq of Intangible Assets	316.6	781.2	551.7	418.9	—
+ Disp of Fixed Assets	11.1	60.3	2.8	46.3	—
+ Purchase of Investments (Equity / Debt)	2,014.1	3.8	23.0	787.8	—
+ Sale of Investments (Equity / Debt)	2,456.9	179.2	111.2	5.9	—
+ Acq of Interests in Joint Ventures	0.0	21.9	0.0	0.0	—
+ Acq of Subsidiaries / Businesses (net)	197.0	0.0	11.4	303.2	—
+ Dividends Received — Investing	0.0	0.0	0.0	2.3	—
+ Interest Received — Investing	146.6	280.8	347.4	328.6	—
+ Other Inflows / (Outflows) — Investing	-1,660.8	-1,189.0	217.4	354.2	—
Cash from Investing Activities	-3,977.8	-4,256.0	-1,875.1	-3,458.4	—
Cash from Financing Activities
+ Buyback / Redemption of Own Shares	0.0	0.0	930.2	0.0	—
+ Payments — Change in Ownership of Subsidiaries	0.0	0.0	22.5	0.0	—
+ Proceeds from Borrowings	2,457.6	1,478.5	2,722.6	719.9	—
+ Repayment of Borrowings	0.0	17.2	1,118.9	1,304.0	—
+ Payment of Lease Liabilities	92.5	146.6	109.8	108.5	—
+ Interest Paid	111.2	250.7	420.3	344.1	—
+ Dividends Paid	439.5	263.6	0.0	232.4	—
+ Other Inflows / (Outflows) — Financing	0.0	0.0	-1.0	0.0	—
Cash from Financing Activities	1,814.4	800.4	119.8	-1,269.2	—
Net Changes in Cash (pre-FX)	223.4	-1,021.0	2,169.3	798.8	—
+ Effect of FX Rate Changes on Cash	-0.1	14.2	9.1	828.8	—
Net Changes in Cash	223.4	-1,006.8	2,178.4	1,627.6	—
Closing Cash	4,392.3	3,385.4	5,563.8	—	—
Reference Items
EBITDA	3,718.6	5,843.0	6,582.8	6,845.7	7,085.3
EBITDA Margin %	14.96	20.15	20.75	20.34	20.28
Free Cash Flow (CFO − Capex)	-333.7	-1,127.0	1,405.1	2,421.7	2,421.7
Free Cash Flow to Equity	—	76.1	2,611.2	1,812.1	—
Free Cash Flow per Basic Share	-5.74	-19.40	24.19	41.70	41.70
Price to Free Cash Flow	—	—	—	—	39.45
Cash Flow to Net Income	1.24	0.77	1.13	1.58	—
Cash Paid for Taxes	717.2	1,766.6	1,731.4	1,832.0	—
Cash Paid for Interest	111.2	250.7	420.3	344.1	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.